Vaborbactam
Based on 42 publication(s) in Google Scholar
Vaborbactam (RPX7009) is a cyclic boronic acid pharmacophore β-lactamase inhibitor.
For research use only. We do not sell to patients.
- Purity: 98.65%
- CAS No.: 1360457-46-0
- Formula: C12H16BNO5S
- Molecular Weight:297.14
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Vaborbactam
More- Nature. 2024 Aug;632(8026):893-902. [Abstract]
- J Med Chem. 2021 Aug 12;64(15):11379-11394. [Abstract]
- Pharmaceutics. 2023 Nov 30;15(12):2705. [Abstract]
- J Clin Microbiol. 2020 Aug 24;58(9):e00932-20. [Abstract]
- Int J Antimicrob Agents. 2024 May 14:107206. [Abstract]
- Antibiotics (Basel). 2024 May 1, 13(5), 416.
- Antibiotics (Basel). 2021 Nov 3;10(11):1341. [Abstract]
- Antibiotics (Basel). 2021 Sep 14;10(9):1110. [Abstract]
- Int J Antimicrob Agents. 2021 Nov;58(5):106439. [Abstract]
- Spectrochim Acta A Mol Biomol Spectrosc. 2020 Apr 5;230:118066. [Abstract]
- Antimicrob Agents Chemother. 2026 Jun 3;70(6):e0126725. [Abstract]
- Antimicrob Agents Chemother. 2026 Feb 19:e0136525. [Abstract]
- Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0001725. [Abstract]
- Antimicrob Agents Chemother. 2025 Jun 2:e0010825. [Abstract]
- Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0077524. [Abstract]
- Antimicrob Agents Chemother. 2024 Aug 19:e0069324. [Abstract]
- Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0034623. [Abstract]
- Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. [Abstract]
- Antimicrob Agents Chemother. 2020 Nov 17;64(12):e00297-20. [Abstract]
- Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00409-20. [Abstract]
- Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02255-19. [Abstract]
- Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02623-18. [Abstract]
- Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00414-18. [Abstract]
- Int J Infect Dis. 2021 May:106:415-420. [Abstract]
- iScience. 2025 Mar 28;28(5):112311. [Abstract]
- ACS Infect Dis. 2024 May 10;10(5):1624-1643. [Abstract]
- ACS Infect Dis. 2022 Mar 11;8(3):400-410. [Abstract]
- ACS Infect Dis. 2021 Apr 9;7(4):826-837. [Abstract]
- Open Forum Infect Di. 2020 Jan 4;7(1):ofz545. [Abstract]
- J Antimicrob Chemother. 2026 Feb 2;81(3):dkag034. [Abstract]
- J Antimicrob Chemother. 2023 Oct 3;78(10):2428-2434. [Abstract]
- J Antimicrob Chemother. 2021 Jul 15;76(8):2071-2078. [Abstract]
- J Antimicrob Chemother. 2021 Feb 11;76(3):653-658. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Mar;44(3):571-585. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Feb;44(2):277-284. [Abstract]
- Bioorg Med Chem. 2021 Sep 15:46:116343. [Abstract]
- Infect Drug Resist. 2021 Jun 30;14:2499-2507. [Abstract]
- bioRxiv. 2025 Nov 27.
- Seoul National University. 2025 Feb.
- bioRxiv. 2025 January 21.
- bioRxiv. 2021 Mar 13.
- RSC Med Chem. 2020 Jan 10;11(4):491-496. [Abstract]
-
Bio/Physico-chemical Assay
-
Microbiological Assay
-
Bio/Physico-chemical Assay
All Beta-lactamase Isoforms
More
Biological Activity
Vaborbactam is a broad spectrum of inhibition of β-lactamases, with particularly potent activity against KPC, CTX-M, SHV, and CMY enzymes[1]. Vaborbactam restores SM 7338 activity for 72.7 to 98.1% of CPE isolates at ≤2 μg/mL, and maximum potentiation is achieved with fixed concentrations of ≥8 μg/mL of the inhibitor (≥96.5% of isolates are inhibited at ≤2 μg/mL of SM 7338-vaborbactam). SM 7338-vaborbactam with a fixed concentration of 8 μg/mL of the inhibitor (MIC50, ≤0.06 μg/mL for all organisms) inhibits 93.7% of the CPE isolates displaying elevated SM 7338 MICs at ≤1 μg/mL[2]. By forming a reversible dative bond with the blactamase, vaborbactam acts as a competitive inhibitor and is not hydrolyzed by the b-lactamase[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1360457-46-0
-
Appearance Solid
-
Molecular Weight 297.14
-
Formula C12H16BNO5S
-
Color Light brown to yellow
-
SMILES
O=C(O)C[C@@H]1CC[C@H](NC(CC2=CC=CS2)=O)B(O)O1
-
Synonyms
RPX7009
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (42)
-
Journal Impact Factor
-
Most Recent
-
Nature
2024 Aug;632(8026):893-902. PMID: 39048820 -
J Med Chem
High-Throughput Crystallography Reveals Boron-Containing Inhibitors of a Penicillin-Binding Protein with Di- and Tricovalent Binding Modes. [Abstract]2021 Aug 12;64(15):11379-11394. PMID: 34337941 -
Pharmaceutics
2023 Nov 30;15(12):2705. PMID: 38140046 -
J Clin Microbiol
NitroSpeed-Carba NP Test for Rapid Detection and Differentiation between Different Classes of Carbapenemases in Enterobacterales. [Abstract]2020 Aug 24;58(9):e00932-20. PMID: 32580949
Vaborbactam purchased from MedChemExpress. Usage Cited in: J Clin Microbiol. 2020 Aug 24;58(9):e00932-20. [Abstract]
100 μl of a Tris-HCl 20 mmol/liter lysis buffer containing 0.1 mM ZnSO4 and vaborbactam (50 μg/ml; MedChemExpress; reference no. HY-19930) in tube 5.A color change from yellow to red in tube 1 only containing water and the absence of any color change (no hydrolysis of nitrocefin) in the other tubes 2 to 5 indicate lack of carbapenemase activity but production of a noncarbapenemase β-lactamase, such as TEM-1 or CTX-M-type enzymes.
-
Int J Antimicrob Agents
MultiRapid ATB NP test for detecting concomitantly susceptibility and resistance of last resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections. [Abstract]2024 May 14:107206. PMID: 38754526 -
-
Antibiotics (Basel)
Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. [Abstract]2021 Nov 3;10(11):1341. PMID: 34827279 -
Antibiotics (Basel)
Rapid Detection of Multiple Classes of β-Lactam Antibiotics in Blood Using an NDM-1 Biosensing Assay. [Abstract]2021 Sep 14;10(9):1110. PMID: 34572692
Vaborbactam purchased from MedChemExpress. Usage Cited in: Antibiotics (Basel). 2021 Sep 14;10(9):1110. [Abstract]
HEPES buffer or plasma samples spiked with 100 mg/L of meropenem, 100 mg/L of Vaborbactam or the mixture of them were subjected to the NDM-1 biosensor; the activity responses (mV) of the NDM-1 biosensor to each agent spiked in HEPES and the net activity response (∆mV) of the NDM-1 biosensor to each agent spiked in plasma are shown in panel.
-
Int J Antimicrob Agents
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. [Abstract]2021 Nov;58(5):106439. PMID: 34547421
Vaborbactam purchased from MedChemExpress. Usage Cited in: Int J Antimicrob Agents. 2021 Nov;58(5):106439. [Abstract]
The β-lactamase L2 of S. maltophilia seemed overall the most susceptible to BLIs, with sulbactam and tazobactam lowering MICATM to 4–8 µg/mL, Vaborbactam (VAB; 0-32 μg/mL) to 2 µg/mL, and AVI and REL, the most effective BLIs, lowered MIC ATM to ≤1 µg/mL.
-
Spectrochim Acta A Mol Biomol Spectrosc
Spectral signal processing approaches for selective quantification of the recently FDA approved brand-new combination of Vaborbactam and Meropenem; for conformity assessment of bulk and batch release. [Abstract]2020 Apr 5;230:118066. PMID: 31958602 -
Antimicrob Agents Chemother
Improved hydrolysis of piperacillin by OXA-48-like R214G variants, a selective advantage under piperacillin-tazobactam exposure. [Abstract]2026 Jun 3;70(6):e0126725. PMID: 42053451 -
Antimicrob Agents Chemother
Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing Klebsiella pneumoniae in the hollow fiber infection model. [Abstract]2026 Feb 19:e0136525. PMID: 41711574 -
Antimicrob Agents Chemother
Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model. [Abstract]2025 Sep 3;69(9):e0001725. PMID: 40741958 -
Antimicrob Agents Chemother
Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction including continuous renal replacement therapy. [Abstract]2025 Jun 2:e0010825. PMID: 40455008 -
Antimicrob Agents Chemother
Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. [Abstract]2024 Nov 6;68(11):e0077524. PMID: 39365068 -
Antimicrob Agents Chemother
Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli. [Abstract]2024 Aug 19:e0069324. PMID: 39158279 -
Antimicrob Agents Chemother
In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. [Abstract]2023 Dec 14;67(12):e0034623. PMID: 37971240 -
Antimicrob Agents Chemother
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa. [Abstract]2023 Jul 18;67(7):e0033923. PMID: 37255469 -
Antimicrob Agents Chemother
Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia. [Abstract]2020 Nov 17;64(12):e00297-20. PMID: 32928733 -
Antimicrob Agents Chemother
Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae. [Abstract]2020 Sep 21;64(10):e00409-20. PMID: 32660988 -
Antimicrob Agents Chemother
Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens. [Abstract]2020 Mar 24;64(4):e02255-19. PMID: 31932381 -
Antimicrob Agents Chemother
In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates. [Abstract]2019 Feb 26;63(3). pii: e02623-18. PMID: 30642943 -
Antimicrob Agents Chemother
Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae. [Abstract]2018 Jul 27;62(8). pii: e00414-18. PMID: 29760136 -
Int J Infect Dis
Evaluation of NitroSpeed-Carba NP test for rapid identification among different classes of carbapenemases in Enterobacterales and Pseudomonas aeruginosa. [Abstract]2021 May:106:415-420. PMID: 33864920 -
iScience
The oxacillinase variant, OXA-1152, in Pandoraea sputorum contributes to discrepancies in carbapenem resistance. [Abstract]2025 Mar 28;28(5):112311. PMID: 40454099 -
ACS Infect Dis
3- O-Substituted Quercetin: an Antibiotic-Potentiating Agent against Multidrug-Resistant Gram-Negative Enterobacteriaceae through Simultaneous Inhibition of Efflux Pump and Broad-Spectrum Carbapenemases. [Abstract]2024 May 10;10(5):1624-1643. PMID: 38652574 -
ACS Infect Dis
Discovery of a Tricyclic β-Lactam as a Potent Antimicrobial Agent against Carbapenem-Resistant Enterobacterales, Including Strains with Reduced Membrane Permeability and Four-Amino Acid Insertion into Penicillin-Binding Protein 3: Structure-Activity-Relationships and In Vitro and In Vivo Activities. [Abstract]2022 Mar 11;8(3):400-410. PMID: 35112852 -
ACS Infect Dis
Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from Burkholderia multivorans. [Abstract]2021 Apr 9;7(4):826-837. PMID: 33723985 -
Open Forum Infect Di
In Vitro Pharmacodynamic Analyses Help Guide the Treatment of Multidrug-Resistant Enterococcus faecium and Carbapenem-Resistant Enterobacter cloacae Bacteremia in a Liver Transplant Patient. [Abstract]2020 Jan 4;7(1):ofz545. PMID: 31993456 -
J Antimicrob Chemother
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]2026 Feb 2;81(3):dkag034. PMID: 41648989 -
J Antimicrob Chemother
Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales. [Abstract]2023 Oct 3;78(10):2428-2434. PMID: 37584236 -
J Antimicrob Chemother
In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. [Abstract]2021 Jul 15;76(8):2071-2078. PMID: 33956969 -
J Antimicrob Chemother
Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. [Abstract]2021 Feb 11;76(3):653-658. PMID: 33258923 -
Eur J Clin Microbiol Infect Dis
In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. [Abstract]2025 Mar;44(3):571-585. PMID: 39704920 -
Eur J Clin Microbiol Infect Dis
In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates. [Abstract]2025 Feb;44(2):277-284. PMID: 39589655 -
Bioorg Med Chem
A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. [Abstract]2021 Sep 15:46:116343. PMID: 34450571 -
Infect Drug Resist
In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant Escherichia coli from Southeastern China. [Abstract]2021 Jun 30;14:2499-2507. PMID: 34234477 -
-
-
-
-
RSC Med Chem
2020 Jan 10;11(4):491-496. PMID: 33479650
Solvent & Solubility
H2O : 5.26 mg/mL (17.70 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 108 mM Sodium carbonate 中最大溶解度
Solubility: 25 mg/mL (84.14 mM); Clear solution; Need ultrasonic
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 27.5 mg/mL (92.55 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hecker SJ, et al. Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. J Med Chem. 2015 May 14;58(9):3682-92. [Content Brief]
[2]. Castanheira M, et al. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with SM 7338 against Serine Carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5454-8. [Content Brief]
[3]. Wong D, et al. Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.3654 mL | 16.8271 mL | 33.6542 mL | 84.1354 mL |
| 5 mM | 0.6731 mL | 3.3654 mL | 6.7308 mL | 16.8271 mL | |
| 10 mM | 0.3365 mL | 1.6827 mL | 3.3654 mL | 8.4135 mL | |
| 15 mM | 0.2244 mL | 1.1218 mL | 2.2436 mL | 5.6090 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.